Drug Trial Radar · NCT00164736
Breastfeeding, Antiretroviral, and Nutrition Study
Last checked: Nov 19, 2026Latest source record: Apr 23, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,369
Actual
Start
Mar 2004
Primary completion
Jan 2010
Study completion Jan 2010
Sponsor
- Lead sponsor
- Centers for Disease Control and PreventionFederal agency
- Sponsor type
- Federal agency
- Collaborators
- University of North Carolina, Chapel Hill; Kamuzu Central Hospital
- First posted
- Sep 14, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 14 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a comparative clinical trial among HIV-infected women and their infants to determine: 1. the benefit of nutritional supplementation given to women during breastfeeding 2. the benefit and safety of antiretroviral (ARV) medications given either to infants or to their mothers to prevent HIV transmission during breastfeeding 3. the feasibility of exclusive breastfeeding followed by early, rapid breastfeeding cessation
Conditions
- HIV Infections
Interventions
Maternal zidovudine/lamivudine/lopinavir-ritonavirDrug
Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food). Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day). Commencing after delivery and through to 28 weeks.
Infant nevirapineDrug
Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg. To 28 weeks while breastfeeding.
Maternal protein and calorie supplementDietary supplement
High energy, nutrient-dense, micronutrient fortified nutritional supplement. Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation. Vitamin A is excluded.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Postpartum weight loss between delivery and 28 weeksTime frame: between delivery and 28 weeks
- Infant HIV status at 28 weeks. (Infants found to have HIV at birth or 2 weeks after delivery will have been disenrolled.)Time frame: birth to 28 weeks
- Exclusive breastfeeding and breastfeeding cessation by 28 weeksTime frame: birth to 28 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kamuzu Central Hospital, Bottom Hospital
Lilongwe, Malawi
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.